Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant
Background: Jump to section Background: Design and methods: Results: Conclusions: Introduction Methods Results Discussion Conclusions Transparency Several studies that evaluated achieving lipid goals have demonstrated an undertreatment of dyslipidemia. We evaluated the use and efficacy of lipid-lowe...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Format: | article |
| Published: |
2014
|
| Online Access: | http://hdl.handle.net/10725/4038 http://dx.doi.org/ 10.1007/BF0012365710.1185/03007995.2014.929095 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.tandfonline.com/doi/abs/10.1185/03007995.2014.929095 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Jump to section Background: Design and methods: Results: Conclusions: Introduction Methods Results Discussion Conclusions Transparency Several studies that evaluated achieving lipid goals have demonstrated an undertreatment of dyslipidemia. We evaluated the use and efficacy of lipid-lowering agents (LLAs) in reducing low-density lipoprotein cholesterol (LDL-C) to recommended levels in the Levant region. Design and methods: Jump to section Background: Design and methods: Results: Conclusions: Introduction Methods Results Discussion Conclusions Transparency A multi-center, cross-sectional survey enrolled 1002 dyslipidemic patients (August 2010 – January 2011) on LLAs for ≥3 months. Collection of data and blood samples was done over one visit. Physicians and patients filled out questionnaires pertaining to dyslipidemia diagnosis and treatment. LDL-C target levels were defined according to international guidelines. Results: Jump to section Background: Design and methods: Results: Conclusions: Introduction Methods Results Discussion Conclusions Transparency The full analysis set included 992 patients. Mean age was 58.0 ± 11.6 years (41% women, 65.7% diabetics and 51.5% had history of coronary heart disease). LLAs were prescribed for primary prevention or secondary prevention or familial hypercholesterolemia in 45.8% and 52.8% and 1.4% of patients; respectively. Overall, 64.0% and 56.8% of the patients attained their LDL-C goal recommended by the NCEP ATP III and TJETF guidelines, respectively. According to the 2004 NCEP ATP III updated guidelines, about 24.8% of the very high risk group attained their LDL goal of ≤70 mg/dL. Smoking, diabetes, metabolic syndrome, history of cardiovascular disease, increased waist circumference, and elevated pre-treatment LDL-C level were all associated with not reaching LDL-C goals. Conclusions: Jump to section Background: Design and methods: Results: Conclusions: Introduction Methods Results Discussion Conclusions Transparency Although the study cohort was a relatively high risk group and might not be representative of the general population, we found that about 60% of enrolled individuals achieved the LDL-C treatment goals and 24.8% of the very high risk group achieved the recommended LDL-C targets of ≤70 mg/dl; national strategies and aggressive awareness campaigns to effectively control lipid levels to recommended target levels, especially in the high risk groups, are urgently needed. |
|---|